Eldred-Evans D, Burak P, Connor MJ, et al. - In this prospective, population-based, blinded cohort study, researchers compared the performance of the following screening tests for prostate cancer: prostate-specific antigen (PSA) testing, magnetic resonance imaging (MRI), and ultrasonography. Screening with a PSA test, MRI (T2 weighted and diffusion), and ultrasonography (B-mode and shear wave elastography) was done among all participants. The proportion of men with positive MRI or ultrasonography (defined as a score of 3-5 or 4-5) or PSA test (defined as PSA ≥3 μg/L) findings was considered the main outcome. Findings revealed that more men were diagnosed with clinically significant cancer, without an increase in the number of men recommended to have a biopsy or overdiagnosed with clinically insignificant cancer, as a result of screening with MRI using a score of 4 or 5 to define a positive test result vs PSA alone at 3 ng/mL or higher, when screening the general population for prostate cancer. No evidence was seen that better performance would be afforded by ultrasonography vs PSA testing alone.